Presented by expert speakers from leading pharmaceutical companies, these workshops will give you advanced insights into topic areas that the event will address
Can’t make the date? Still register to receive the recording afterwards.
Virtual Panel Discussion: Strategies for Accelerating the Treatment and Response Rate of Cancer Immunotherapy
14th July 2020 | 10.30am BST
Moderated by PHILIP BEER, Cancer Genomics Lead, NHS
During the past few decades, research has provided breakthroughs that have enhanced our understanding of the mechanisms and pathways that regulate the immune system’s response to cancer. However, despite these advances, obstacles still exist for the field of cancer immunotherapy. This panel discussion will discuss the following challenges that need to be overcome to improve patient response rate to immuno-oncology:
- Predicting treatment efficacy and patient response
- The need for additional biomarkers
- The development of resistance to cancer immunotherapies
- The lack of clinical study designs that are optimised to determine efficacy
Philip Beer, Cancer Genomics Lead, NHS
Dr Philip Beer is a physician scientist and precision oncology specialist who holds diverse roles across the healthcare, academic and commercial sectors, united by the singular goal of leveraging genomic technologies to improve outcomes for cancer patients. Philip is currently working with two NHS Genomic Laboratory Hubs to accelerate their provision of genomic cancer analysis. In the drug discovery space, he leads a translational medicine programme at a small pharmaceutical company and provides clinical genomics support for a UK-wide clinical trials network (Precision-Panc). He is also part of the management team for the International Cancer Genome Consortium’s new ARGO project (Accelerating Research in Genomic Oncology).
Anguraj Sadanandam, Team Leader, The Institute for Cancer Research
Anguraj Sadanandam completed his interdisciplinary Ph.D. from the USA, and continued postdoc with Professors Joe Gray and Douglas Hanahan. He then briefly worked at Swiss Institute of Bioinformatics. He is currently a tenured Team Leader (Associate Professor) at the Institute of Cancer Research (ICR), London. He has honorary appointments with Royal Marsden Hospital and Mayo Clinic. His team focuses on stratified and precision cancer therapy based on his pioneering gastrointestinal cancer studies. He published pioneering publications (multiple Nature Medicines, Cancer Discovery, Annals of Oncology) related to the above strategies.
Markus Zettl, Director Immuno-Oncology, Pieris Pharmaceuticals
Before joining Pieris Pharmaceuticals as Director Immuno-Oncology overseeing pre-clinical development of Pieris´s innovative pipeline projects, Dr. Zettl was Project Leader at Boehringer-Ingelheim from 2011, leading antibody programs in the field of Immuno-Oncology from early preclinical into clinical phases. During his PhD and postdoctoral studies, he worked in a variety of areas of cancer biology at the EMBL in Heidelberg Germany and at the MRC-LMB in Cambridge UK. Research topics covered molecular mechanisms of how oncolytic viruses exploit the host cytoskeleton and the impact of metallo-protease (TACE) activation on cytokine and growth factor signalling with implications for cancer and inflammatory disorders. Dr. Zettl authored numerous high impact publications and patents in the field of Immuno-Oncology.
The S-TIR™ technology platform: Vaccines based on evolutionary conserved immunological mechanisms for the treatment of both allergy and cancer
Thursday 19th March | 3PM GMT
Presented by Geert Mudde, Founder, Chief Scientific Officer & Managing Director at S-TARget therapeutics.
- How to control positive and negative checkpoints in oncology
- The central role of plasmacytoid dendritic cells in immunological diseases
- The induction of unprecedented polyclonal immune responses in the absence of side effects
Our free webinar is for professionals involved in Immunotherapy development interested in learning more about immunological mechanisms for the treatment of both allergies and cancer.
This is a free event open to all, so why not register and benefit from the expertise of our speakers?
Human Studies of Inflammation, Cardiometabolic Disease and Psoriasis: A Proliferative Environment
Thursday 7th May | 1:30pm BST
Hosted by Nehal Mehta, Senior Investigator, Section of Inflammation and Cardiometabolic Diseases, NIH
- Cardiometabolic diseases include obesity, dyslipidemia and dysglycemia, all of which increase risk of cardiovascular disease.
- Inflammation is associated with development of cardiometabolic diseases.
- Treatment of chronic systemic inflammation with a monoclonal antibody blocking IL1-beta improved cardiovascular outcomes and decreased incident of lung cancer.
- Psoriasis is a chronic systemic inflammatory disease which provides a human model to better understand these observations.
Nehal Mehta attended an accelerated seven-year biomedical program where he received his B.A. in 1997 with honors and M.D. in 2001 with Distinction from The George Washington University, and a M.S.C.E. in genetic epidemiology from the University of Pennsylvania in 2009. Following medical school, Dr. Mehta did his internship, residency, and chief medical residency in internal medicine at the University of Pennsylvania Hospital, followed by a fellowship in cardiovascular diseases, nuclear cardiology, and preventive cardiology. Following this, he did a post-doctoral fellowship in genetic epidemiology with a focus on inflammation and lipoproteins at the University of Pennsylvania’s Center for Clinical Epidemiology and Biostatistics (CCEB) and Institute of Translational Medicine and Therapeutics (ITMAT). In 2009, Dr. Mehta joined the faculty in Cardiovascular Medicine at the University of Pennsylvania School of Medicine and at the CCEB as an Associate Scholar. Dr. Mehta came to the NIH in 2012 as the inaugural Lasker Clinical Research Scholar, joining the NHLBI’s Cardiovascular and Pulmonary Branch. In addition to the Lasker Scholarship, Dr. Mehta has received numerous local and national awards and honors, including being named a Fellow of the American College of Physicians and American Heart Association. He is actively involved in several foundations and organizations in membership and leadership capacities including the American Heart Association and National Psoriasis Foundation. He is the editor for the section on cardiovascular, metabolic, and lipoprotein translation in the Journal of Translational Medicine and serves as a reviewers for several international grant organizations as well as biomedical journals.